Maratha Headlines

Osteoarthritis Pipeline Analysis: 130+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Osteoarthritis Pipeline Analysis: 130+ Companies are Working to Improve the Treatment Space | DelveInsight

November 08
20:53 2022
Osteoarthritis Pipeline Analysis: 130+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Osteoarthritis Pipeline Insight, 2022,” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Osteoarthritis Pipeline Insight Report

  • DelveInsight’s Osteoarthritis Pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis.
  • The leading Osteoarthritis Companies such as Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
  • Promising Osteoarthritis Therapies such as V120083, Naproxen, EP-104IAR, Hyalgan, SI-613, Oral Calcitonin, APPA, and others
  • The Osteoarthritiscompanies and academics are working to assess challenges and seek opportunities that could influence R&D Osteoarthritis. The therapies under development are focused on novel approaches to treat/improve Osteoarthritis.
  • In theOsteoarthritis Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Request a sample and discover the recent advances in Osteoarthritis treatment @ Osteoarthritis Pipeline Report

 

Osteoarthritis Overview

Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. Osteoarthritis is most likely to affect the joints that bear most of weight, such as the knees and feet. Joints that the person use a lot in everyday life, such as the joints of the hand, are also commonly affected. The main symptoms of osteoarthritis are pain and sometimes stiffness in the affected joints. The pain tends to be worse when the person move the joint or at the end of the day. Osteoarthritis is a leading cause of disability and source of societal cost in older adults. With an ageing and increasingly obese population, this syndrome is becoming even more prevalent than in previous decades.

 

Recent Breakthroughs of Osteoarthritis Treatment Landscape

  • In January 2021 Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML).
  • In January 2022, Astex Pharmaceuticals, Inc. announced that the European Commission (EC) has granted orphan-drug designation (ODD) to the oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML).
  • In April 2021, Ampio Pharmaceuticals announced that it had received a positive response from the U.S. Food and Drug Administration (FDA) on its plans for its AP-013 Phase III trial for the intra-articular injection of Ampion, its novel anti-inflammatory, for patients suffering from severe osteoarthritis of the knee (OAK).
  • In April 2021, Biosplice Therapeutics announced the execution of a licensing agreement that grants Samil the right to develop and exclusively commercialize lorecivivint (SM04690) for the treatment of knee osteoarthritis (“OA”) in the Republic of Korea. 
  • In April 2021, Eupraxia Pharmaceuticals announced that it has entered into an agreement (the “CTO Agreement”) with NBCD A/S (“NBCD”) to conduct Eupraxia’s EP-104IAR Phase 2 clinical trial that will initiate later this year.
  • In October 2020, Merck KGaA entered into an out-licensing agreement with Novartis for the development of an osteoarthritis clinical-stage programme. Under the terms of the deal, Merck will out-license M6495 to Novartis for further evaluation in osteoarthritis patients.
  • In September 2020, Sorrento Therapeutics released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) in the reduction of OsteoArthritis (OA) knee pain.
  • X0002 is a new anti-inflammatory drug that acts as an inhibitor of Cyclooxygenase. It is currently in the Phase III stage of development for Osteoarthritis and is being developed by Techfields Pharma. 
  • In July 2020, the FDA granted the Fast Track Designation to X0002 for Knee Osteoarthritis and the low back. 

 

Find out more about Osteoarthritis Medication @ Osteoarthritis Treatment

 

Osteoarthritis Emerging Drugs

  • Lorecivivint: Biosplice Therapeutics
  • CYP 004: Cynata Therapeutics
  • JTA-004: Bone Therapeutics
  • SMUP-IA-01: Medipost
  • TTAX03: Tissue Tech

 

DelveInsight’s Osteoarthritis Pipeline report covers around 130+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Learn more about the novel and emerging Osteoarthritis Pipeline therapies @ Osteoarthritis Clinical Trials

 

Scope of the Osteoarthritis Pipeline Report

  • Coverage- Global
  • Osteoarthritis Assessment by Product Type
  • Osteoarthritis Assessment by Stage and Product Type
  • Osteoarthritis Assessment by Route of Administration
  • Osteoarthritis Assessment by Stage and Route of Administration
  • Osteoarthritis Assessment by Molecule Type
  • Osteoarthritis Assessment by Stage and Molecule Type
  • Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
  • Osteoarthritis Therapies- V120083, Naproxen, EP-104IAR, Hyalgan, SI-613, Oral Calcitonin, APPA, and others.

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Osteoarthritis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Osteoarthritis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Lorecivivint: Biosplice Therapeutics
  9. Mid Stage Products (Phase II)

10. TTAX03: Tissue Tech

11. Early Stage Products (Phase I)

12. GLPG-0555: Gilead Sciences

13. Preclinical Stage Products

14. Protego-PD: Plakous Therapeutics

15. Inactive Products

16. Osteoarthritis Key Companies

17. Osteoarthritis Key Products

18. Osteoarthritis- Unmet Needs

19. Osteoarthritis- Market Drivers and Barriers

20. Osteoarthritis- Future Perspectives and Conclusion

21. Osteoarthritis Analyst Views

22. Osteoarthritis Key Companies

23. Appendix

 

Dive deep into rich insights for drugs for Osteoarthritis treatment, visit @ New Drug for Osteoarthritis Treatment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/